ReviewACS pharmacology & translational science2026
Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Disseminated melanoma, particularly of rare subtypes such as mucosal or uveal melanoma, is a difficult to treat, deadly disease characterized by poor median survival and resistance to a wide range of treatments. Despite new approvals, such as novel immunotherapeutics, there is a significant need for effective therapeutic modalities. Given the successes in the development of targeted radiopharmaceutical diagnostic agents and therapies for other cancers (the so-called theranostics), assessing the efficacy of these strategies in the context of melanoma appears as the next logical step. Here we aim to provide an overview of recent advances in the development of preclinical and clinical melanoma-specific radiopharmaceuticals. Where applicable, we will highlight their relevance in the context of rare subtypes of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.